Longevity & AgingBlocking Epac1 Halts Lung Scarring by Preserving a Key Anti-Fibrosis Protein
Idiopathic pulmonary fibrosis (IPF) is a fatal lung-scarring disease with no cure. Researchers found that a signaling protein called Epac1 is abnormally elevated in IPF lung tissue and drives fibroblast proliferation and scar formation. By blocking Epac1—either genetically or with a small-molecule inhibitor called AM-001—the team reduced fibrosis markers, blunted TGF-β and IL-6 signaling, and protected mice from bleomycin-induced lung injury. The key mechanism involves the neddylation pathway: Epac1 promotes attachment of the protein NEDD8 to FoxO3a, tagging it for degradation. AM-001 blocks this process, restoring FoxO3a levels and its anti-fibrotic, cell-cycle-inhibiting functions. Results were validated in human IPF fibroblasts and precision-cut lung slices.
